PLX
Protalix Biotherapeutics Inc
2.70$
-1.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +1.4% | -64.3% | +259.5% | +33.3% | +1.4% | -44.5% | +54.8% | +14.0% | -48.9% | +270.0% | -41.0% | – | |
| – | +81.0% | -70.6% | +263.4% | -11.4% | -53.6% | +110.5% | -28.2% | +41.8% | -44.5% | -10.7% | +88.1% | – | |
| – | -70.1% | -29.7% | +250.6% | +138.5% | +49.5% | -86.5% | +406.4% | -2.7% | -52.7% | +557.9% | -59.0% | – | |
| – | -15.5% | -6.9% | +2.6% | +1.2% | +37.6% | -15.7% | +72.4% | -25.5% | +26.1% | -3.7% | -19.8% | – | |
| – | +200.0% | -97.1% | +1,647.3% | +55.2% | +3.7% | -83.5% | +0.8% | +11.6% | +20.4% | +23.9% | -28.8% | – | |
| – | -1.3% | -17.2% | +7.4% | -13.2% | +27.4% | -14.7% | +41.8% | -14.2% | +23.9% | -7.5% | -12.0% | – | |
| – | – | – | – | – | +80.6% | -157.5% | – | +81.8% | -318.6% | – | -77.9% | – | |
| – | +68.3% | -49.6% | -5.9% | -18.5% | -98.0% | +0.0% | +12,950.0% | -77.0% | +112.8% | -49.6% | +156.0% | – | |
| – | – | – | – | – | +90.4% | -151.0% | – | +238.7% | -313.3% | – | -77.0% | – | |
| – | -387.2% | – | – | – | +35.4% | -113.7% | – | -123.3% | – | +287.9% | -61.7% | – | |
| – | – | – | – | – | +100.7% | -155.7% | – | +1,336.0% | -333.7% | – | -79.4% | – | |
| – | – | – | – | – | +71.2% | -144.1% | – | +54.7% | -243.5% | – | -73.5% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.